Celldex reiterated as a Focus Pick at Roth Capital Roth Capital reiterated Celldex as its Focus Pick citing its broad pipeline and the potential for accelerated approval for either ORR or PFS. Shares are Buy rated with a $16 price target.
News For CLDX From The Last 14 Days
Check below for free stories on CLDX the last two weeks.
Subscribe for More Information